← FDA DRUG APPROVALS

FDA ANDA · ANDA209933

NEOSTIGMINE METHYLSULFATE

Sponsor: AMPHASTAR PHARMS INC

APPLICATION
ANDA209933
TYPE
ANDA
ORIGINAL APPROVAL
2017-09-25
LATEST ACTION
2025-10-24
ROUTE
INTRAVENOUS
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription

Products

NEOSTIGMINE METHYLSULFATEPrescription
NEOSTIGMINE METHYLSULFATE 5MG/10ML (0.5MG/ML) · SOLUTION · INTRAVENOUS
NEOSTIGMINE METHYLSULFATEPrescription
NEOSTIGMINE METHYLSULFATE 10MG/10ML (1MG/ML) · SOLUTION · INTRAVENOUS

Approval history

2025-10-24Labeling · Supplement 2 · standardAP
2022-05-19Labeling · Supplement 1 · standardAP
2017-09-25UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →